This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (2) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Eterovic, D. Articles by Primorac, D. Search for Related Content PubMed PubMed Citation Articles by Eterovic, D. Articles by Primorac, D. Social Bookmarking                         What's this?

Lower Contribution of Factor V Leiden or G202104 Mutations to Ischemic Stroke in Patients With Clinical Risk Factors

Pair-Matched Case-Control Study

Davor Eterovi, PhD

Department of Physiology and Biophysics, University Hospital Split, Split, Croation, eterovic{at}bsb.mefst.hr

Marina Titli, MD

Department of Neurology, University Hosptial Split, Split, Croatia

Viktor uli, MD

Department of Medicine, University Hospital Split, Split, eterovic{at}bsb.mefst.hr

Renata Zadro, PhD

Department of Laboratory Diagnostics, University Hospital Rebro, Zagreb, Croatia

Dragan Primorac, MD, PhD

Department of Medical Diagnostics, Medical School at Split, University Hospital Split, Split

It was suggested that factor V Leiden and prothrombin G20210A mutations increase the risk of ischemic stroke only in combination with clinical risk factors of arterial ischemic disease. In these studies the controls were derived from the general population, with fewer clinical risk factors, which might have produced biased results. The factor V Leiden and prothrombin G20210A mutations were examined by polymerase chain reaction technique in 120 ischemic stroke patients and 120 controls younger than 65 years of age. Each patient had his own control, tightly matched in clinical risk factors. The prevalences of factor V Leiden and prothrombin G20210A mutations in patients were 8.3% (P = 0.02) and 7.5% (P = 0.04), respectively, and 2.5% for controls for both mutations. All carriers were single heterozygotes. In patients, but not in controls, the carriers of either mutation were mostly women and with fewer clinical risk factors for arterial ischemic events. In particular, considering both mutations as a single coagulation deficit, their presence increased the likelihood of ischemic stroke (odds ratio [OR] = 3.6; 95% confidence interval [CI] 1.4—9.3), especially among women (OR = 4.6; 95% CI: 1.2—17.8), normotensive persons (OR = 9.2; 95% CI: 1.1—17.8) and those having normal cholesterol (OR = 5.9; 95% CI: 1.6—21.2) and triglyceride serum concentrations (OR = 4.3; 95% CI: 1.5—12.8). In the studied sample of adult North Mediterranean population younger than 65 years the prevalences of factor V Leiden and prothrombin G20210A mutations were greater in patients with ischemic stroke than in matched controls. Unlike in studies with unmatched controls, we observed an apparently negative interaction of these mutations with clinical risk factors.

Key Words: Factor V Leiden • G20210A • Stroke.

Clinical and Applied Thrombosis/Hemostasis, Vol. 13, No. 2, 188-193 (2007)
DOI: 10.1177/1076029606298999


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Kuruvilla, G. M. Norris, S. Manjila, A. R. Xavier, and S. Chaturvedi Factor V Leiden Mutation in Reocclusion After Intra-Arterial Thrombolysis Stroke, February 1, 2009; 40(2): 660 - 662. [Abstract] [Full Text] [PDF]